Four new arene–ruthenium(II) complexes [(η⁶-p-cymene)RuCl(dpm)], where dpm are hexa-(L3–L5) and meso-substituted (L6) dipyrromethene ligands, were synthesized. These ligands and the corresponding complexes were thoroughly characterized by elemental analysis and spectroscopic techniques (MS, IR, ¹H, ¹³C NMR, and UV–vis), and the structures of one ligand and three ruthenium complexes were determined by X-ray single-crystal analysis. The DNA-binding ability of the Ru-3–Ru-6 complexes was evaluated by UV–vis DNA titration. Compound Ru-3 exhibited the highest binding energy, outperforming the complexes containing a dipyrrin ligand substituted by chlorides (Ru-4 and Ru-5) or a meso-substituted dipyrrin (Ru-6). Molecular docking revealed that the hypothetical Ru-1 and Ru-2 complexes, which contain iodide ligands in the dipyrrin structures, showed higher DNA-binding affinities than Ru-3. Computational calculations supported the experimental results, confirming that Ru-3 has a higher affinity for DNA than the other complexes.

This paper presents the synthesis and characterization of Schiff base ligands (L) derived from NH-pyrazole-indole and their ruthenium(II) complexes of the general formula [Ru(p-cymene)(L)Cl₂]. The structural characterization of the ligands and ruthenium complexes was performed using a range of analytical methods, including infrared spectroscopy (IR), Raman spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, ultraviolet-visible (UV-Vis) spectroscopy, elemental analysis, mass spectrometry(ESI-MS), density functional theory (DFT) calculations, and single-crystal X-ray diffraction crystallography for two of the four synthesized compounds. Schiff base ligands (L) derived from NH-pyrazole-indole and their ruthenium(II) complexes were evaluated against antibiotic-resistant bacteria. The effect of substituting the ligand with methoxy groups on biological activity was assessed. The antibacterial activity, Minimal Inhibitory Concentration (MIC), and Minimal Bactericidal Concentration (MBC) of the free ligands and the ruthenium compounds were measured against six bacterial isolates (Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Shigella dysenteriae) and two control strains (Enterococcus faecalis ATCC 29212 and Enterobacter cloacae ATCC 13047) from the ESKAPE group of highly antibiotic-resistant pathogens. The free ligands were inactive, whereas all four ruthenium complexes displayed notable antibacterial activity. In particular, compounds Ru3 and Ru4 exhibited higher activity against Staphylococcus aureus than the Trimethoprim control, with MIC values of 15.60 µg/mL, compared with an MIC > 64 µg/mL for Trimethoprim. The activity of those two complexes was similar to that of Gentamicin against this strain. Molecular docking calculations suggested a possible mechanism of action through binding of the complexes to the active site of S. aureus PBP2a.